$PAXH
PREAXIA HEALTH CARE PAYMENT SYSTEMS INC.

2024 Q2 Form 10-Q Financial Statement

#000126246324000052 Filed on April 17, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.120K $6.370K $36.12K
YoY Change -85.79% -82.36% -0.69%
% of Gross Profit
Research & Development $2.436K $371.00
YoY Change 556.6% -96.47%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.610K $8.810K $36.49K
YoY Change -87.65% -75.86% -22.15%
Operating Profit -$8.810K -$36.49K
YoY Change -75.86% -22.03%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.610K -$8.810K -$36.49K
YoY Change -87.65% -75.86% -22.03%
Income Tax
% Of Pretax Income
Net Earnings -$4.610K -$8.810K -$36.49K
YoY Change -87.65% -75.86% -22.03%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 19.77M shares 19.77M shares 19.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.00 $1.190K $30.00
YoY Change 0.0% 3866.67% -86.36%
Cash & Equivalents $14.00 $1.194K $32.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.00 $1.194K $32.00
YoY Change 133.33% 3631.25% -85.45%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $14.00 $1.194K $32.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $14.00 $1.194K $32.00
YoY Change 133.33% 3631.25% -85.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $466.9K $465.9K $366.7K
YoY Change 17.21% 27.07% -46.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.717M $1.717M $1.699M
YoY Change 1.1% 1.08% 40.72%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.396M $2.393M $2.259M
YoY Change 4.33% 5.9% 8.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.396M $2.393M $2.259M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.396M $2.393M $2.259M
YoY Change 4.33% 5.9% 8.0%
SHAREHOLDERS EQUITY
Retained Earnings -$5.128M -$5.124M -$4.992M
YoY Change 1.98% 2.65%
Common Stock $19.77K $19.77K $19.77K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.396M -$2.392M -$2.259M
YoY Change
Total Liabilities & Shareholders Equity $14.00 $1.194K $32.00
YoY Change 133.33% 3631.25% -85.45%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$4.610K -$8.810K -$36.49K
YoY Change -87.65% -75.86% -22.03%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.620K -$3.540K -$7.950K
YoY Change -36.04% -55.47% -50.28%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.440K 2.870K 7.800K
YoY Change -56.66% -63.21% -51.55%
NET CHANGE
Cash From Operating Activities -3.620K -3.540K -7.950K
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 2.440K 2.870K 7.800K
Net Change In Cash -1.180K -670.0 -150.0
YoY Change 3833.33% 346.67% -236.36%
FREE CASH FLOW
Cash From Operating Activities -$3.620K -$3.540K -$7.950K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Entity Address City Or Town
EntityAddressCityOrTown
Calgary
dei Entity Address State Or Province
EntityAddressStateOrProvince
AB
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
T3C 3W2
dei City Area Code
CityAreaCode
403
dei Local Phone Number
LocalPhoneNumber
850-4120
dei Security12g Title
Security12gTitle
Common Stock, $0.001 par value
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
165934 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
158348 usd
CY2024Q1 paxh Accounts Payable And Accrued Liabilities Related Party
AccountsPayableAndAccruedLiabilitiesRelatedParty
300000 usd
CY2023Q2 paxh Accounts Payable And Accrued Liabilities Related Party
AccountsPayableAndAccruedLiabilitiesRelatedParty
240000 usd
CY2024Q1 paxh Due To Related Party Current
DueToRelatedPartyCurrent
75130 usd
CY2023Q2 paxh Due To Related Party Current
DueToRelatedPartyCurrent
64952 usd
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
191329 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
173067 usd
CY2024Q1 paxh Liability For Unissued Shares Current
LiabilityForUnissuedSharesCurrent
134792 usd
CY2023Q2 paxh Liability For Unissued Shares Current
LiabilityForUnissuedSharesCurrent
134792 usd
CY2024Q1 paxh Promissory Note Related Party
PromissoryNoteRelatedParty
466817 usd
CY2023Q2 paxh Promissory Note Related Party
PromissoryNoteRelatedParty
466817 usd
CY2024Q1 paxh Convertible Note Payable Related Party
ConvertibleNotePayableRelatedParty
1058760 usd
CY2023Q2 paxh Convertible Note Payable Related Party
ConvertibleNotePayableRelatedParty
1058760 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2392762 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2296736 usd
CY2024Q1 us-gaap Liabilities
Liabilities
2392762 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2296736 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
19768 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2655236 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
57197 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5123769 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5028931 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2391568 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2296730 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1194 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6 usd
CY2024Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q1 paxh Consulting Fees
ConsultingFees
30442 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2259391 usd
us-gaap Net Income Loss
NetIncomeLoss
-94838 usd
us-gaap Net Income Loss
NetIncomeLoss
-118927 usd
paxh Consulting Fees
ConsultingFees
60000 usd
paxh Consulting Fees
ConsultingFees
90442 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
3472 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
2996 usd
us-gaap Professional Fees
ProfessionalFees
15623 usd
us-gaap Professional Fees
ProfessionalFees
12536 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2902 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2679 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13079 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10734 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2436 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
371 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6136 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5215 usd
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
8810 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
36488 usd
us-gaap Operating Expenses
OperatingExpenses
94838 usd
us-gaap Operating Expenses
OperatingExpenses
118927 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8810 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-36488 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-94838 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8810 usd
us-gaap Net Income Loss
NetIncomeLoss
-118927 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
CY2024Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19767698 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19767698 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19767698 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19767698 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
19767698 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2382758 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-8810 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2391568 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2296730 usd
us-gaap Net Income Loss
NetIncomeLoss
-94838 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2391568 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2222903 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-36488 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2259391 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-2140464 usd
us-gaap Net Income Loss
NetIncomeLoss
-118927 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
60000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
90000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
7585 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3028 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27253 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31955 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
18262 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
4992 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
11764 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
27303 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1585 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
567 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
28441 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
31728 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1188 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-227 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
259 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1194 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Profit Loss
ProfitLoss
-94838 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27253 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-2391568 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5123769 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84A_eus-gaap--UseOfEstimates_z5knt2b1Kg9h" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><i><span style="text-decoration: underline"><span id="xdx_86F_zGgtoqALpcr">Use of Estimates</span> </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify">The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in these consolidated financial statements and accompanying notes. Although these estimates are based on management’s knowledge of current events and actions that our company may undertake in the future, actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"><i> </i></p>
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6136 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5215 usd
CY2024Q1 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19767698 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19767698 shares

Files In Submission

Name View Source Status
0001262463-24-000052-index-headers.html Edgar Link pending
0001262463-24-000052-index.html Edgar Link pending
0001262463-24-000052.txt Edgar Link pending
0001262463-24-000052-xbrl.zip Edgar Link pending
ex31.htm Edgar Link pending
ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
paxh-20240229.xsd Edgar Link pending
paxh229202410q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
paxh-20240229_cal.xml Edgar Link unprocessable
paxh-20240229_def.xml Edgar Link unprocessable
paxh-20240229_lab.xml Edgar Link unprocessable
paxh229202410q_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
paxh-20240229_pre.xml Edgar Link unprocessable